These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33460673)

  • 1. Interpreting SARS-CoV-2 seroprevalence, deaths, and fatality rate - Making a case for standardized reporting to improve communication.
    Cavataio J; Schnell S
    Math Biosci; 2021 Mar; 333():108545. PubMed ID: 33460673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of over-diagnosis in serological testing. Implications for communications strategies.
    Biggeri A; Forni S; Braga M
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):184-192. PubMed ID: 33412809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
    COVID-19 Cumulative Infection Collaborators
    Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
    Barchuk A; Skougarevskiy D; Kouprianov A; Shirokov D; Dudkina O; Tursun-Zade R; Sergeeva M; Tychkova V; Komissarov A; Zheltukhina A; Lioznov D; Isaev A; Pomerantseva E; Zhikrivetskaya S; Sofronova Y; Blagodatskikh K; Titaev K; Barabanova L; Danilenko D
    PLoS One; 2022; 17(6):e0266945. PubMed ID: 35704649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
    Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
    Yang W; Kandula S; Huynh M; Greene SK; Van Wye G; Li W; Chan HT; McGibbon E; Yeung A; Olson D; Fine A; Shaman J
    Lancet Infect Dis; 2021 Feb; 21(2):203-212. PubMed ID: 33091374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country.
    Molenberghs G; Buyse M; Abrams S; Hens N; Beutels P; Faes C; Verbeke G; Van Damme P; Goossens H; Neyens T; Herzog S; Theeten H; Pepermans K; Abad AA; Van Keilegom I; Speybroeck N; Legrand C; De Buyser S; Hulstaert F
    Contemp Clin Trials; 2020 Dec; 99():106189. PubMed ID: 33132155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.
    Bortz RH; Florez C; Laudermilch E; Wirchnianski AS; Lasso G; Malonis RJ; Georgiev GI; Vergnolle O; Herrera NG; Morano NC; Campbell ST; Orner EP; Mengotto A; Dieterle ME; Fels JM; Haslwanter D; Jangra RK; Celikgil A; Kimmel D; Lee JH; Mariano MC; Nakouzi A; Quiroz J; Rivera J; Szymczak WA; Tong K; Barnhill J; Forsell MNE; Ahlm C; Stein DT; Pirofski LA; Goldstein DY; Garforth SJ; Almo SC; Daily JP; Prystowsky MB; Faix JD; Fox AS; Weiss LM; Lai JR; Chandran K
    mSphere; 2021 Apr; 6(2):. PubMed ID: 33883259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study.
    Post LA; Issa TZ; Boctor MJ; Moss CB; Murphy RL; Ison MG; Achenbach CJ; Resnick D; Singh LN; White J; Faber JMM; Culler K; Brandt CA; Oehmke JF
    J Med Internet Res; 2020 Dec; 22(12):e24286. PubMed ID: 33216726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut.
    Mahajan S; Caraballo C; Li SX; Dong Y; Chen L; Huston SK; Srinivasan R; Redlich CA; Ko AI; Faust JS; Forman HP; Krumholz HM
    Am J Med; 2021 Jun; 134(6):812-816.e2. PubMed ID: 33617808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of case fatality rate of SARS-CoV-2 infection in the Spanish Autonomous Communities between March and May 2020.
    V MS; A CM; A BG; F VS; A SF; V OQ; A SC;
    PLoS One; 2021; 16(12):e0260769. PubMed ID: 34860848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staff SARS-CoV-2 Seroprevalence and Mental Health as Key Factors in University Response to COVID-19 Pandemic.
    Lopes DG; Henriques AR; Santos-Dias M; Nunes-da-Silva C; Gonçalves J; de Sousa RD; Abdulghani S; Eletério J; Braga SJ; Soares H; Branco JC; Canhão H; Rodrigues AM
    Front Public Health; 2021; 9():689919. PubMed ID: 34222187
    [No Abstract]   [Full Text] [Related]  

  • 15. Age-specific mortality and immunity patterns of SARS-CoV-2.
    O'Driscoll M; Ribeiro Dos Santos G; Wang L; Cummings DAT; Azman AS; Paireau J; Fontanet A; Cauchemez S; Salje H
    Nature; 2021 Feb; 590(7844):140-145. PubMed ID: 33137809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of serological surveys of antibodies to SARS-CoV-2 in the United States to estimate parameters needed for transmission modeling and to evaluate and improve the accuracy of predictions.
    Glasser JW; Feng Z; Vo M; Jones JN; Clarke KEN
    J Theor Biol; 2023 Jan; 556():111296. PubMed ID: 36208669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and Public Health: Looking Back, Moving Forward.
    Juliano C; Castrucci B; Fraser MR
    J Public Health Manag Pract; 2021; 27 Suppl 1, COVID-19 and Public Health: Looking Back, Moving Forward():S1-S4. PubMed ID: 33239556
    [No Abstract]   [Full Text] [Related]  

  • 18. The importance of utilizing travel history metadata for informative phylogeographical inferences: a case study of early SARS-CoV-2 introductions into Australia.
    Porter AF; Featherstone L; Lane CR; Sherry NL; Nolan ML; Lister D; Seemann T; Duchene S; Howden BP
    Microb Genom; 2023 Aug; 9(8):. PubMed ID: 37650865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study.
    Pallett SJC; Rayment M; Patel A; Fitzgerald-Smith SAM; Denny SJ; Charani E; Mai AL; Gilmour KC; Hatcher J; Scott C; Randell P; Mughal N; Jones R; Moore LSP; Davies GW
    Lancet Respir Med; 2020 Sep; 8(9):885-894. PubMed ID: 32717210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States.
    Levorson RE; Christian E; Hunter B; Sayal J; Sun J; Bruce SA; Garofalo S; Southerland M; Ho S; Levy S; Defillipi C; Peake L; Place FC; Hourigan SK
    PLoS One; 2021; 16(11):e0259823. PubMed ID: 34748615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.